Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases

  • Jae Won Hyun
  • , Hye Lim Lee
  • , Woo Kyo Jeong
  • , Hye Jung Lee
  • , Jong Hwa Shin
  • , Ju Hong Min
  • , Byoung Joon Kim
  • , Seung Woo Kim
  • , Ha Young Shin
  • , Jeeyoung Oh
  • , Woojun Kim
  • , Hyun June Shin
  • , Sun Young Oh
  • , Hyunjin Kim
  • , Young Min Lim
  • , So Young Huh
  • , Eun Bin Cho
  • , Tai Seung Nam
  • , Seung Han Lee
  • , Sun Young Kim
  • Sa Yoon Kang, Suk Geun Han, Eun Hee Sohn, Seol Hee Baek, Byung Jo Kim, Sang Soo Lee, Jin Myoung Seok, Yoon Ho Hong, Seong Il Oh, Jong Kuk Kim, Kyong Jin Shin, Ohyun Kwon, Joong Yang Cho, Jong Seok Bae, So Yeon Kim, Yeseul Kim, Min Young Lee, Su Hyun Kim, Ho Jin Kim*
*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

Abstract

We aimed to compare seroprevalence of anti-myelin oligodendrocyte glycoprotein (MOG) and anti-aquaporin-4 (AQP4) antibodies in Korean adults with inflammatory demyelinating diseases (IDDs) of the central nervous system (CNS), based on a multicenter nationwide database. Sera were analyzed using a live cell–based assay for MOG and AQP4 antibodies. Of 586 Korean adults with IDDs of the CNS, 36 (6.1%) and 185 (31.6%) tested positive for MOG and AQP4 antibodies, respectively. No participant showed double positivity. Seroprevalence of MOG antibodies was about five times lower than that of AQP4 antibodies in a large cohort of Korean adults with IDDs of the CNS.

Original languageEnglish
Pages (from-to)964-967
Number of pages4
JournalMultiple Sclerosis Journal
Volume27
Issue number6
DOIs
StatePublished - 2021.05

Keywords

  • adult
  • Aquaporin-4
  • myelin oligodendrocyte glycoprotein
  • prevalence

Quacquarelli Symonds(QS) Subject Topics

  • Medicine

Fingerprint

Dive into the research topics of 'Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases'. Together they form a unique fingerprint.

Cite this